Ronald J Santilli Net Worth

The estimated Net Worth of Ronald J Santilli is at least $3.86 Milión dollars as of 11 September 2017. Ronald Santilli owns over 5,775 units of Cutera Inc stock worth over $34,508 and over the last 20 years Ronald sold CUTR stock worth over $3,823,715.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ronald Santilli CUTR stock SEC Form 4 insiders trading

Ronald has made over 45 trades of the Cutera Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently Ronald sold 5,775 units of CUTR stock worth $233,483 on 11 September 2017.

The largest trade Ronald's ever made was exercising 63,700 units of Cutera Inc stock on 2 March 2015 worth over $664,391. On average, Ronald trades about 9,620 units every 62 days since 2004. As of 11 September 2017 Ronald still owns at least 50,012 units of Cutera Inc stock.

You can see the complete history of Ronald Santilli stock trades at the bottom of the page.

What's Ronald Santilli's mailing address?

Ronald's mailing address filed with the SEC is C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE, CA, 94005.

Insiders trading at Cutera Inc

Over the last 21 years, insiders at Cutera Inc have traded over $58,122,420 worth of Cutera Inc stock and bought 1,064,292 units worth $26,108,997 . The most active insiders traders include Kevin P Connors, J Daniel Plants a David A Gollnick. On average, Cutera Inc executives and independent directors trade stock every 22 days with the average trade being worth of $13,243. The most recent stock trade was executed by Michael Karavitis on 14 May 2024, trading 63,603 units of CUTR stock currently worth $165,368.

What does Cutera Inc do?

cutera was established in the san francisco bay area (brisbane) in 1998 by veteran laser and optical engineers. as the pioneer of nd:yag technology, cutera® is the trusted authority in face + body energy-based medical aesthetic technologies that practitioners around-the-world turn to for innovation, sophistication and performance. at cutera, we’re always looking forward; developing new solutions, products and industry-leading services designed around the needs of medical aesthetic community—delivering better results, faster and safer than ever before. cutera’s premium portfolio of products include: xeo®, trusculpt® and excel v™. in 2014, cutera introduced two new exciting additions to their family of premium products: excel hr™ for high-speed, comfortable, hair removal and enlighten™, the industry’s first picosecond + nanosecond + 2 wavelength high-powered laser system. today, our worldwide presence is represented in 40 countries, with direct operations in north america, france, austra

Complete history of Ronald Santilli stock trades at Cutera Inc

Cutera Inc executives and stock owners

Cutera Inc executives and other stock owners filed with the SEC include:

• David Mowry,
  Chief Executive Officer, Director
• R. Jason Richey,
  President
• David H. Mowry,
  CEO & Director
• Rohan Seth,
  Chief Financial Officer
• Gregory Barrett,
  Independent Director
• J. Daniel Plants,
  Independent Chairman of the Board
• Timothy O'Shea,
  Independent Director
• Joseph Whitters,
  Independent Director
• Katherine Zanotti,
  Independent Director
• J. Daniel Plants,
  Exec. Chairman
• Anne Werdan,
  Director - Investor Relations
• Darren Alch,
  Vice President, General Counsel, Secretary
• Rohan Seth,
  Chief Financial Officer
• Dr. Michael Karavitis,
  Exec. VP & Chief Technology Officer
• Jerry P Widman,
  Director
• Miguel Pardos,
  EVP, International Sales
• James A. Reinstein,
  President and CEO
• Clinton Severson,
  Director
• David B Apfelberg,
  Director
• Larry Laber,
  EVP, North America Sales
• Kevin P Connors,
  President and CEO
• David A Gollnick,
  VP of Research and Development
• Thomas John Liolios,
  VP of International
• Keith J Sullivan,
  Director
• Nicholas Sheridan Lewin,
  Director
• Sandra A. Gardiner,
  EVP & Chief Financial Officer
• Elisha W Finney,
  Director
• Guy P Nohra,
  Director
• Michael J Levernier,
  VP of Clinical Development
• Associates Iii Lp Medventure,
  10% owner
• Guy Palta California Partne...,
  
• Kathleen A Maynor,
  VP of Regulary Affairs & QA
• Associates Management Iii C...,
  10% owner
• Guy Palta Partnersalta Cali...,
  
• Dean Macfarland,
  
• Michael W Sasnett,
  
• W Mark Lortz,
  Director
• Leonard C De Benedictis,
  Chief Technology Officer
• White Annette Campbell,
  Director
• Robert John Jr Shine,
  VP of International
• Ronald J Santilli,
  CFO & VP of Finance and Admin.
• John Connors,
  VP of North American Sales
• Jeryl L Hilleman,
  Director
• Michael Karavitis,
  EVP, Chief Technology Officer
• Sheila Hopkins,
  Director
• Juliane Park,
  Director
• Janet D. Widmann,
  Director
• Kevin J Cameron,
  Director
• Stuart Drummond,
  Interim CFO
• Taylor C. Harris,
  Chief Executive Officer
• Jeffrey S Jones,
  Chief Operating Officer
• Stephana Eilene Patton,
  Chief Legal Officer